Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Current Deferred Revenue (2016 - 2024)

Historic Current Deferred Revenue for Seres Therapeutics (MCRB) over the last 9 years, with Q2 2024 value amounting to $7.9 million.

  • Seres Therapeutics' Current Deferred Revenue rose 18122.12% to $7.9 million in Q2 2024 from the same period last year, while for Jun 2024 it was $7.9 million, marking a year-over-year increase of 18122.12%. This contributed to the annual value of $7.7 million for FY2023, which is 8149.8% up from last year.
  • As of Q2 2024, Seres Therapeutics' Current Deferred Revenue stood at $7.9 million, which was up 18122.12% from $8.1 million recorded in Q1 2024.
  • Over the past 5 years, Seres Therapeutics' Current Deferred Revenue peaked at $22.6 million during Q4 2020, and registered a low of $2.4 million during Q1 2023.
  • In the last 5 years, Seres Therapeutics' Current Deferred Revenue had a median value of $13.8 million in 2020 and averaged $13.2 million.
  • Per our database at Business Quant, Seres Therapeutics' Current Deferred Revenue plummeted by 8837.63% in 2023 and then surged by 24128.79% in 2024.
  • Seres Therapeutics' Current Deferred Revenue (Quarter) stood at $22.6 million in 2020, then dropped by 25.59% to $16.8 million in 2021, then plummeted by 74.68% to $4.3 million in 2022, then surged by 81.5% to $7.7 million in 2023, then grew by 2.48% to $7.9 million in 2024.
  • Its Current Deferred Revenue stands at $7.9 million for Q2 2024, versus $8.1 million for Q1 2024 and $7.7 million for Q4 2023.